Clinical Trials
135
Active:1
Completed:117
Trial Phases
6 Phases
Early Phase 1:1
Phase 1:70
Phase 2:7
+3 more phases
Drug Approvals
3
PHILIPPINES:3
Clinical Trials
Distribution across different clinical trial phases (110 trials with phase data)• Click on a phase to view related trials
Phase 1
70 (63.6%)Phase 3
22 (20.0%)Phase 2
7 (6.4%)Phase 4
6 (5.5%)Not Applicable
4 (3.6%)Early Phase 1
1 (0.9%)A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 44
- Registration Number
- NCT07180771
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
Not Applicable
Recruiting
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mgDrug: Metformin HCl 1000 mg
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 52
- Registration Number
- NCT07083388
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)
Not Applicable
Recruiting
- Conditions
- Diabete Mellitus
- Interventions
- Drug: Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mgDrug: Metformin HCl 1000 mg
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT07083401
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT07069335
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa District, Korea, Republic of
A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
Phase 4
Recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 204
- Registration Number
- NCT06972732
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seocho District, South Korea
- Prev
- 1
- 2
- 3
- 4
- 5
- 27
- Next
News
No news found